Novartis Aktie

117,95 EUR +0,50 EUR +0,43 %

09:51:59

STU

109,68 CHF +1,18 CHF +1,09 %

09:47:45

SWX

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.224,11 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

28.10.25Dow JonesPress Release: Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

27.10.25BenzingaAvidity Biosciences Soars After $72 Per Share Novartis Takeover

27.10.25BenzingaAvidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

26.10.25Business TimesNovartis agrees to buy Avidity in US$12 billion biotech deal

26.10.25Financial TimesNovartis to buy Avidity Biosciences for $12bn

25.10.25Dow JonesPress Release: Novartis showcases significant -2-

25.10.25Dow JonesPress Release: Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

23.10.25ZacksGear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

22.10.25BenzingaNovartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

22.10.25ZacksNovartis (NVS) is an Incredible Growth Stock: 3 Reasons Why

22.10.25ZacksHere's Why Alcon (ALC) is a Strong Momentum Stock

22.10.25Dow JonesPress Release: Novartis Cosentyx(R) meets primary -2-

22.10.25Dow JonesPress Release: Novartis Cosentyx(R) meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

22.10.25Dow JonesPress Release: Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

21.10.25BenzingaAlcon Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

19.10.25Dow JonesPress Release: PSMAddition data show Novartis -2-

19.10.25Dow JonesPress Release: PSMAddition data show Novartis Pluvicto(TM) delays progression to end-stage prostate cancer

17.10.25BenzingaNovartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

17.10.25Dow JonesPress Release: Novartis Kisqali(R) 5-year NATALEE -2-

17.10.25Dow JonesPress Release: Novartis Kisqali(R) 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

17.10.25Dow JonesPress Release: Novartis Scemblix(R) receives -2-

17.10.25Dow JonesPress Release: Novartis Scemblix(R) receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

16.10.25BenzingaNovartis Strengthens Kidney Disease Pipeline With Promising Data

16.10.25Dow JonesPress Release: Novartis Fabhalta(R) (iptacopan) -2-

16.10.25Dow JonesPress Release: Novartis Fabhalta(R) (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

10.10.25PR NewswireCIBC to transfer 11 European Canadian Depositary Receipt listings to TSX

09.10.25ZacksThe Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne

08.10.25ZacksTop Stock Reports for SAP, Novartis & Philip Morris

08.10.25ZacksHere's Why Novartis (NVS) is a Strong Value Stock

06.10.25Zacks3 Reasons Growth Investors Will Love Novartis (NVS)

06.10.25ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term

02.10.25ZacksNovartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

30.09.25PR NewswireNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

30.09.25Dow JonesPress Release: Novartis receives FDA approval for -2-

30.09.25Dow JonesPress Release: Novartis receives FDA approval for Rhapsido(R) (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

29.09.25BenzingaForecasting The Future: 10 Analyst Projections For Alcon

29.09.25BenzingaPharma's Direct-To-Patient Wave Hits Novartis Next

29.09.25Dow JonesPress Release: Novartis to Launch -2-

29.09.25Dow JonesPress Release: Novartis to Launch Direct-to-Patient Platform for Cosentyx(R) (secukinumab) in the US

29.09.25Dow JonesPress Release: Novartis announces commencement of -2-

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.